Neurology · 1992 · 97 citations · 0 references
PharmacyPharmacokineticsPharmacologyBioavailabilityDrug MetabolismHepatic PharmacokineticsAntiepileptic PharmacologyAntiepileptic PharmacotherapyDrug DispositionFirst-pass MetabolismGastrointestinal PharmacologyPharmacokinetics In Liver DiseaseAntiepileptic Drug PharmacokineticsCarbamazepine PharmacologyFirst-pass Metabolism EffectsFirst-pass Metabolism ReductionLiver First-pass EffectOral Drug BioavailabilityPhenytoin Therapy
Antiepileptic drugs, especially carbamazepine and phenytoin, are potent liver enzyme inducers. Since praziquantel, the drug used to treat neurocysticercosis, undergoes extensive liver first-pass metabolism, we carried out a prospective study to verify whether there was a decrease in oral bioavailability induced by carbamazepine and phenytoin. Carbamazepine and phenytoin significantly decreased concentrations of praziquantel, due to increased clearance secondary to induction of first pass-liver metabolism. The magnitude of the decrease is surprisingly high and may be responsible for failures of treatment.